[Obtainment of cerebral evoked potentials at the time of stimulation of micromelic extremities].

I. LOSSKY-NEKHOROCHEFF,J. Siegfried,A. Fourment,J. Hindermeyer

Confinia Neurologica

Abstract:

What problem does this paper attempt to address?

Brain tumor related epilepsy: pathophysiological approaches and rational management of antiseizure medication

Sabine Seidel,Tim Wehner,Dorothea Miller,Jörg Wellmer,Uwe Schlegel,Wenke Grönheit

DOI: https://doi.org/10.1186/s42466-022-00205-9

2022-09-05

Neurological Research and Practice

Abstract:Abstract Background Brain tumor related epilepsy (BTRE) is a common complication of cerebral tumors and its incidence is highly dependent on the type of tumor, ranging from 10–15% in brain metastases to > 80% in low grade gliomas. Clinical management is challenging and has to take into account aspects beyond the treatment of non-tumoral epilepsy. Main body Increasing knowledge about the pathophysiology of BTRE, particularly on glutamatergic mechanisms of oncogenesis and epileptogenesis, might influence management of anti-tumor and BTRE treatment in the future. The first seizure implies the diagnosis of epilepsy in patients with brain tumors. Due to the lack of prospective randomized trials in BTRE, general recommendations for focal epilepsies currently apply concerning the initiation of antiseizure medication (ASM). Non-enzyme inducing ASM is preferable. Prospective trials are needed to evaluate, if AMPA inhibitors like perampanel possess anti-tumor effects. ASM withdrawal has to be weighed very carefully against the risk of seizure recurrence, but can be achievable in selected patients. Permission to drive is possible for some patients with BTRE under well-defined conditions, but requires thorough neurological, radiological, ophthalmological and neuropsychological examination. Conclusion An evolving knowledge on pathophysiology of BTRE might influence future therapy. Randomized trials on ASM in BTRE with reliable endpoints are needed. Management of withdrawal of ASMs and permission to drive demands thorough diagnostic as well as neurooncological and epileptological expertise.
Wild Seizing Gliomas! Time-Dependent Characteristics and Prognosis of Glioblastoma-Related Epilepsy

Anteneh M. Feyissa

DOI: https://doi.org/10.1177/15357597241253374

2024-05-10

Epilepsy Currents

Abstract:Epilepsy Currents, Ahead of Print. Characteristics and Prognosis of Tumor-Related Epilepsy During Tumor Evolution in Patients With IDH Wild-Type Glioblastoma Pallud J, Roux A, Moiraghi A, Aboubakr O, Elia A, Guinard E, Oppenheim C, Tauziede-Espariat A, Parraga E, Gavaret M, Chrètien F, Huberfeld G, Zanello M. Neurology. 2024;102(1): e207902. doi:10.1212/WNL.0000000000207902 Background and Objectives:Tumor-related epilepsy is a well-known symptom of glioblastoma. However, the particular characteristics of epileptic seizures related to glioblastoma, isocitrate dehydrogenase (IDH)-wild-type is almost unexplored longitudinally during the whole course of the disease. We assessed tumor-related epilepsy and seizure control during tumor evolution and the prognostic significance of tumor-related epilepsy.Methods:We performed an observational, retrospective single-center study at one tertiary referral neuro-oncology surgical center (2000-2020). We included adult patients treated for a newly diagnosed supratentorial glioblastoma, IDH-wild-type with available preoperative and postoperative MRI and with available epileptic seizure status at diagnosis. To determine factors associated with tumor-related epilepsy or seizure control, univariate analyses were performed using the χ2 or Fisher exact tests for categorical variables and the unpaired t test or Mann-Whitney rank-sum test for continuous variables. Predictors associated with tumor-related epilepsy and seizure control in unadjusted analysis were entered into backward stepwise logistic regression models.Results:One thousand six patients were enrolled. The cumulative incidence of tumor-related epilepsy increased during tumor evolution (33.1% at diagnosis, 44.7% after oncologic treatment, 52.4% at progression, and 51.8% at the end-of-life phase) and is related to tumor features (cortex involvement, no necrosis, and small volume). Uncontrolled epileptic seizures increased during tumor evolution (20.1% at diagnosis, 32.0% after oncologic treatment, 46.7% at progression, and 41.1% at the end-of-life phase). Epileptic seizure control after oncologic treatment was related to seizure features (uncontrolled before oncologic treatment and focal-to-bilateral tonic-clonic seizures) and to the extent of resection. Epileptic seizure control at tumor progression was related to seizure features (presence at diagnosis and uncontrolled after oncologic treatment) and to the time to progression. Tumor-related epilepsy at diagnosis was a predictor of a longer overall survival (adjusted hazard ratio, 0.78; 95% CI 0.67-0.90; p < 0.001) independent of age, Karnofsky Performance Status score, tumor location and volume, extent of resection, standard combined chemoradiotherapy, levetiracetam use, and MGMT promoter methylation.Discussion:The progression of tumor-related epilepsy with the evolution of glioblastoma, IDH-wild-type, and the effects of surgery on seizure control argue for proper antiseizure medication and maximal safe resection. Tumor-related epilepsy is an independent predictor of a longer survival.

clinical neurology
Glioma-related epilepsy in patients with diffuse high-grade glioma after the 2016 WHO update: seizure characteristics, risk factors, and clinical outcomes

Lianwang Li,Shengyu Fang,Guanzhang Li,Kenan Zhang,Ruoyu Huang,Yinyan Wang,Chuanbao Zhang,Yiming Li,Wei Zhang,Zhong Zhang,Qiang Jin,Dabiao Zhou,Xing Fan,Tao Jiang

DOI: https://doi.org/10.3171/2020.12.jns203351

IF: 5.408

2022-01-01

Journal of Neurosurgery

Abstract:OBJECTIVE The aim of this study was to investigate the epidemiological characteristics, associated risk factors, and prognostic value of glioma-related epilepsy in patients with diffuse high-grade gliomas (DHGGs) that were diagnosed after the 2016 updated WHO classification was released. METHODS Data from 449 patients with DHGGs were retrospectively collected. Definitive diagnosis was reaffirmed according to the 2016 WHO classification. Seizure outcome was assessed using the Engel classification at 12 months after surgery. Univariate and multivariate analyses were performed to identify risk factors associated with preoperative and postoperative glioma-related epilepsy. Lastly, the prognostic value of glioma-related epilepsy was evaluated by Kaplan-Meier and Cox analysis. RESULTS The incidence of glioma-related epilepsy decreased gradually as the malignancy of the tumor increased. Age < 45 years (OR 2.601, p < 0.001), normal neurological function (OR 3.024, p < 0.001), and lower WHO grade (OR 2.028, p = 0.010) were independently associated with preoperative glioma-related epilepsy, while preoperative glioma-related epilepsy (OR 7.554, p < 0.001), temporal lobe involvement (OR 1.954, p = 0.033), non–gross-total resection (OR 2.286, p = 0.012), and lower WHO grade (OR 2.130, p = 0.021) were identified as independent predictors of poor seizure outcome. Furthermore, postoperative glioma-related epilepsy, rather than preoperative glioma-related epilepsy, was demonstrated as an independent prognostic factor for overall survival (OR 0.610, p = 0.010). CONCLUSIONS The updated WHO classification seems conducive to reveal the distribution of glioma-related epilepsy in DHGG patients. For DHGG patients with high-risk predictors of poor seizure control, timely antiepileptic interventions could be beneficial. Moreover, glioma-related epilepsy (especially postoperative glioma-related epilepsy) is associated with favorable overall survival.

surgery,clinical neurology
Seizures in glioma patients: An overview of incidence, etiology, and therapies

Niyatee Samudra,Tresa Zacharias,Aaron Plitt,Bradley Lega,Edward Pan

DOI: https://doi.org/10.1016/j.jns.2019.07.026

IF: 4.4

2019-09-01

Journal of the Neurological Sciences

Abstract:Gliomas are fatal brain tumors, and even low-grade gliomas (LGGs) have an average survival of less than a decade. Seizures are a common presentation of gliomas, particularly LGGs, and substantially impact quality of life. Glioma-related seizures differ from other focal epilepsies in their pathogenesis and in the likelihood of refractory epilepsy. We review factors that predict seizure activity and response to treatment, optimal pharmacologic and surgical management of glioma-related epilepsy, and the benefit of using newer anti-seizure medications in patients with gliomas. As surgery is so often beneficial with seizure reduction, we discuss oncologic and epilepsy surgery perspectives. Treatment of gliomas has the potential to ameliorate seizures and increase rates of seizure freedom. Prospective, well-powered studies are needed to provide more definitive answers for practitioners taking care of glioma patients with seizures.

neurosciences,clinical neurology
The Potential of Seizure to Predict Prognosis in Glioblastoma Patients: A retrospective Study

G nerhan,Emin IL,Zeynep lar,Ahmet BELEN

DOI: https://doi.org/10.5455/annalsmedres.2023.10.279

2023-01-01

Annals of Medical Research

Abstract:Objective Glioma, particularly glioblastoma (GBM), represents a prevalent and aggressive primary brain tumor with limited curative options. Epileptic seizures often manifest as a common clinical symptom in these patients, but their prognostic significance remains debated. This study aimed to retrospectively analyze the clinical presentations, tumor characteristics, and the impact of seizures on the prognosis of GBM patients. Materials and Methods A total of 113 adult patients with histologically confirmed GBM treated between April 2018 and January 2022 were included in this retrospective analysis. Data encompassed clinical symptoms, preoperative and postoperative seizures, tumor localization, overall survival (OS), and other relevant factors. Statistical analysis was performed to assess the relationships between seizures and various prognostic parameters. Results Seizures were present in 39.8% of GBM patients, with 20 patients experiencing both preoperative and postoperative seizures. Preoperative and postoperative seizures were not significantly associated with differences in prognosis (p>0.05). Tumor localization, OS, Karnofsky performance score, and length of hospital stay showed significant differences between patients with and without seizures (p<0.05). Complete resection was achieved in 90.3% of patients, leading to a relatively lower incidence of postoperative seizures. Conclusion Seizures in GBM patients are associated with OS, Karnofsky performance score, and hospitalization duration, independently of other factors. The presence of seizures serves as a valuable prognostic indicator for GBM, prompting further investigation into its influence on patient outcomes, quality of life, and socioeconomic aspects of survival. These findings emphasize the importance of early seizure management in GBM patients and the need for tailored treatment strategies.
Postoperative seizure control in patients with tumor-associated epilepsy

Andrew Neal,Andrew Morokoff,Terence John O'Brien,Patrick Kwan

DOI: https://doi.org/10.1111/epi.13562

IF: 6.74

Epilepsia

Abstract:Objective: The patterns of postoperative seizure control and response to antiepileptic drugs (AEDs) in tumor-associated epilepsy (TAE) are poorly understood. We aim to document these characteristics in patients with supratentorial gliomas. Methods: This was a retrospective analysis of 186 patients with supratentorial gliomas. Seizure patterns were classified into four groups: A, no postoperative seizure; B, early postoperative seizure control within 6 months; C, fluctuating seizure control; and D, never seizure-free. Rates and duration of seizure freedom, subsequent seizure relapse, and response to AED were analyzed. Results: Among patients included, 49 (26.3%) had grade II, 28 (15.1%) had grade III, and 109 (58.6%) had grade IV glioma. Outcome pattern A was observed in 95 (51.1%), B in 22 (11.8%), C in 45 (24.2%), and D in 24 (12.9%). One hundred nineteen patients had at least one seizure and were classified as having TAE. Compared to pattern A, pattern B was predicted by histologic progression; pattern C by tumor grade, preoperative seizure, and histologic progression, and pattern D by preoperative seizure and gross total resection. Among patients with TAE, 57.5% of grade II, 68.2% of grade III, and 26.3% of grade IV experienced a period of 12-month seizure freedom. After first 12-month seizure remission, 39.1%, 60.0%, and 13.3% of grade II, III, and IV gliomas, respectively, experienced subsequent seizure; 22.6% of those with TAE reached terminal seizure freedom of at least 12 months on their first postoperative AED regimen, 6.5% on their second regimen, and 5.4% on subsequent regimens. Significance: Distinct patterns of postoperative seizure control exist in gliomas; they have specific risk factor profiles, and we hypothesize these correspond to unique pathogenic mechanisms. Twelve-month seizure freedom with subsequent relapse is frequent in grade II-III gliomas. Response to AEDs is markedly poorer than with non-TAE, highlighting the complex epileptogenicity of gliomas.
The Clinical Features and Influencing Factors of Surgical Efficacy in Glioneuronal Tumors Associated-Epilepsy

Ming Wenjie,Zhang Yinxi,Shen Chunhong,Wang Zhongjin,Wang Shuang,Zheng Zhe,Ding Meiping,Zhu Junming

DOI: https://doi.org/10.3760/cma.j.issn.1001-2346.2018.12.004

2018-01-01

Abstract:Objective To investigate the clinical features of surgical-resected glioneuronal tumors associated-epilepsy and to explore the influencing factors of surgical efficacy.Methods A retrospectively study was conducted on 39 consecutive epilepsy patients with glioneuronal tumors confirmed by postoperative pathology who underwent epileptogenic focus resection at Epilepsy Center of the Second Affiliated Hospital,Zhejiang University School of Medicine from July 2012 to December 2016.Their clinical features and prognostic factors were analyzed (Engel grade Ⅰ:good outcome;grade Ⅱ-Ⅳ:poor outcome).Results A total of 39 cases consisted of 28 cases of gangliogliomas and 11 dysembryoplastic neuroepithelial tumors.The average age of onset was 21.5 ± 13.5 years old,and children and young patients (below 35 years old) accounted for 84.6％ (33 cases) of all cases.The median duration of course was 2 years.Thirty-one cases presented with refractory epilepsy courses.The tumor location was temporal lobe in 27 cases and frontal lobe in 9.The average follow-up time of 39 patients was 1.9 ± 0.8 years.Among them,Engel grade Ⅰ was reported in 28 (71.8％) cases,grade Ⅱ in 8,grade Ⅲ in 2 and grade Ⅳ in 1.No recurrence was found in brain tumors.Compared with the poor outcome group,the proportion of patients with good outcome was higher in the rate of undergoing intraoperative cortical EEG monitoring (21/28 vs.4/11),and the difference was statistically significant (P =0.033).Other clinical features,including gender,age of onset,course of disease,operation age,epilepsy type,drug response,tumor location and focal cortical dysplasia,had no correlation with the outcome (all P ＞ O.05).Conclusions Glioneuronal tumors associated-epilepsy have a relative higher prevalence in children and young people with common location at temporal lobe and clinical features of refractory course.Surgical resection may lead to good outcome.Intraoperative electrocorticography monitoring could assist in localization of epileptogenic foci and postoperative control of seizures.
Clinical Characteristics of Low‐grade Tumor‐related Epilepsy and Its Predictors for Surgical Outcome

Chenmin He,Lingli Hu,Cong Chen,Zhe Zheng,Bo Jin,Yao Ding,Shuang Wang,Mei-Ping Ding,Junming Zhu,Shan Wang

DOI: https://doi.org/10.1002/acn3.51387

IF: 5.43

2021-01-01

Annals of Clinical and Translational Neurology

Abstract:AbstractObjectivesLow‐grade tumors are the most common neoplasms inducing focal epilepsy; however, the short‐ and medium‐term efficacy of surgery in epilepsy patients with low‐grade tumors remains underappreciated. This study aims to summarize the clinical characteristics of epilepsy patients with low‐grade tumors and to identify factors associated with postsurgical seizure‐free outcomes.MethodsWe retrospectively reviewed consecutive patients with low‐grade tumors who underwent subsequent epilepsy surgery in our epilepsy center, between 2012 and 2018 with a minimum follow‐up of 1 year. Using Engel’s classification and Kaplan–Meier survival analysis, we assessed postoperative seizure freedom over time. Demographical, electroclinical, and other presurgical evaluations were then evaluated for association with postoperative seizure outcome.ResultsThe cohort included a total of 132 patients: 79 males and 53 females. Among them, 110 (83.33%) were seizure‐free through their last follow‐up. The Engel class I outcomes were 90.15%, 87.76%, 85.53%, 82.46%, and 73.17% at the end of the 1st, 2nd, 3rd, 4th, and 5th postoperative years, respectively. Multivariate logistic analysis revealed that longer epilepsy duration (p < 0.001, OR 1.091, 95% CI 1.040–1.144) and incomplete resection (p = 0.009, OR 3.673, 95% CI 1.393–9.684) were independently associated with seizure recurrence through the last follow‐up.ConclusionsSurgical treatment for seizure control in patients with low‐grade tumors provides excellent short‐ and median‐term outcomes.
Long-term seizure outcome after epilepsy surgery of neuroglial tumors

Attila Rácz,Philipp Müller,Albert Becker,Nico Hoffmann,Theodor Rüber,Valeri Borger,Hartmut Vatter,Rainer Surges,Christian E. Elger

DOI: https://doi.org/10.3389/fneur.2024.1384494

IF: 3.4

2024-05-24

Frontiers in Neurology

Abstract:Purpose: Neuroglial tumors are frequently associated with pharmacorefractory epilepsies. However, comprehensive knowledge about long-term outcomes after epilepsy surgery and the main prognostic factors for outcome is still limited. We sought to evaluate long-term outcomes and potential influencing factors in a large cohort of patients who underwent surgery for neuroglial tumors in a single-center setting. Methods: The study analyzed the outcomes of 107 patients who underwent epilepsy surgery for neuroglial tumors between 2001 and 2020 at the Department of Epileptology, University Hospital Bonn, in Germany. The outcomes were evaluated using Engel classification. Differences in outcome related to potential prognostic factors were examined using the Chi2-test, Fisher's exact test and sign test. Additionally, stepwise logistic regression analysis was employed to identify independent prognostic factors. Results: Complete seizure freedom (Engel Class IA) was achieved in 75% of the operated patients at 12 months, and 56% at the last follow-up visit (70.4 ± 6.2 months, median: 40 months). Completeness of resection was a crucial factor for both 12-month follow-up outcomes and the longest available outcomes, whereas lobar tumor localization, histology (ganglioglioma vs. dysembryoplastic neuroepithelial tumor), history of bilateral tonic–clonic seizures prior to surgery, invasive diagnostics, side of surgery (dominant vs. non-dominant hemisphere), age at epilepsy onset, age at surgery, and epilepsy duration did not consistently impact postsurgical outcomes. Among temporal lobe surgeries, patients who underwent lesionectomy and lesionectomy, including hippocampal resection, demonstrated similar outcomes. Conclusion: Neuroglial tumors present as excellent surgical substrates in treating structural epilepsy. To achieve an optimal postsurgical outcome, a complete lesion resection should be pursued whenever possible.

neurosciences,clinical neurology
Glioma-related epilepsy following low-grade glioma surgery

Amir Saam Youshani,Calvin Heal,Jing X Lee,Michael Younis,Rajiv Mohanraj,Helen Maye,Matthew Bailey,David Coope,Pietro I D'Urso,Konstantina Karabatsou

DOI: https://doi.org/10.1093/noajnl/vdae127

2024-07-20

Abstract:Background: Epileptic seizures commonly burden low-grade glioma (LGG) patients and negatively impact quality of life, neurocognition, and general patient health. Anti-seizure medications (ASMs) are used to manage seizures but can result in undesired side effects. Our aim was to report our experience in epilepsy in one of the largest case series of LGG patients (reclassified in accordance with the WHO 2021 classification). Furthermore, we evaluate our postoperative seizure frequency difference between LGG patients who use preoperative ASMs and ones with no ASMs. Methods: Data were retrospectively collected from Salford Royal Hospital electronic records and Neuro-Oncology database from 2006 to 2022. Descriptive statistics were performed for demographic analysis, while multivariable analysis was used to determine postoperative seizure-free outcomes. Results: In total, 257 operations were performed on 206 patients. Postoperatively, 114 patients suffered from seizures, and approximately 45.2% of patients developed seizures at 3-12 months postsurgery, with the odds higher in patients on preoperative ASMs. There was no evidence to suggest a higher postoperative seizure rate in patients undergoing awake craniotomy versus general anesthetic. The extent of resection (EOR) was inversely related to seizure failure, with gross-total resection showing a statistically significant reduction in seizures in comparison to all other surgical resections. Conclusions: In our experience, there is no evidence to suggest a reduced postoperative seizure outcome when prescribing preoperative ASMs. EOR is an independent prognosticator for postoperative seizure failure with all other variables demonstrating nonsignificance. Overall, a larger study can investigate the role of ASMs in LGG in greater detail.
To be or not to be: The dilemma over the prognostic role of epilepsy at presentation in patients with glioblastoma – a systematic review and meta-analysis

Jessica Rossi,Francesco Cavallieri,Maria Chiara Bassi,Francesco Venturelli,Giulia Toschi,Giulia Di Rauso,Chiara Lucchi,Benedetta Donati,Romana Rizzi,Marco Russo,Massimo Bondavalli,Corrado Iaccarino,Giacomo Pavesi,Antonino Neri,Giuseppe Biagini,Alessia Ciarrocchi,Paolo Giorgi Rossi,Anna Pisanello,Franco Valzania

DOI: https://doi.org/10.1186/s12885-024-13249-8

IF: 4.638

2024-12-05

BMC Cancer

Abstract:Despite some evidence of a possible link between epileptogenesis and tumorigenesis in glioblastoma, the prognostic value of epilepsy at presentation has been debated over the years. We performed a systematic review and meta-analysis to summarize all published data evaluating the prognostic significance of seizures as a presenting manifestation of glioblastoma. A comprehensive search of five databases from inception to December 2023 was conducted. Included studies underwent meta-analysis, with subgroup analyses performed to identify sources of heterogeneity. Fifteen studies were included in the analysis. Seizures were considered a favorable prognostic factor in seven studies, while eight studies found no differences in overall survival between patients with seizures and those with other presenting symptoms. Eleven studies were included in the meta-analysis. The overall pooled analysis indicated a potentially favorable prognostic impact of seizures at the clinical onset of glioblastoma (HR 0.73; 95% CI 0.61–0.87). However, subgroup analysis within studies focusing on IDH-wild type cases showed no discernible impact from preoperative seizures. Retrospective design, poor quality in reporting results, and heterogeneity in tumor characteristics and therapies are the main limitations of included studies.

oncology
Next Generation Sequencing Mutational Profiles of Gliomas Reveal Clinical and Genetic Factors Predicting Refractory Postoperative Seizures

Poojan Shukla,Minh P. Nguyen,Jacob Young,Anthony T. Lee,Edward Chang

DOI: https://doi.org/10.1227/neu.0000000000002810_129

IF: 5.315

2024-04-01

Neurosurgery

Abstract:INTRODUCTION: Postoperative seizures are a common complication of gliomas following resection, but little is known about their course and the role of tumor biology in their development. METHODS: Single-center retrospective review of adults who underwent surgical management of glioma with targeted next generation sequencing of tumor samples obtained 2017-2020. Univariate analysis for relevant cohort characteristics and adjustment with multivariate regression was performed. RESULTS: Among 341 patients with at least 3 months of follow-up, 174 (51.0%) experienced postoperative seizures and 89 (26.1%) had refractory seizures, defined as seizures occurring monthly or more frequently. Patients with refractory seizures were younger, presented with seizure, had IDH-mutated tumors, and had recurrent tumors. Postoperative refractory seizures had a median length of 9.4 months. In a multivariate analysis adjusting for age, seizures at presentation, newly diagnosed or recurrent status, WHO grade, and IDH status, PIK3R1 mutation emerged as an independent predictor of increased odds of developing refractory seizures (log(OR) 0.89 [0, 1.8], p = 0.044) with PIK3CA mutations trending towards significance (log(OR) 0.66 [-0.12, 1.4], p = 0.09). In another stratified multivariate analysis, CKD4 (log(OR) 1.9 [0.42, 3.4], p = 0.014), PIK3CA (log(OR) 1.3 [0.15, 2.4], p = 0.026) emerged as predictors of refractory seizure among recurrent tumors while presenting with seizure (log(OR) 0.81, [0.08, 1.5], p = 0.03) was the only significant predictor among newly diagnosed tumors. CONCLUSIONS: PIK3R1 and PIK3CA mutations were independent predictors of increased odds of postoperative refractory seizures, with CDK4 mutations as an additional predictor among recurrent tumors. Seizures at presentation predicted refractory postoperative seizures in newly diagnosed tumors, suggesting the need for close clinical follow-up in these patients. Future analysis of this cohort will enable better characterization of the influence of tumor mutational profile on postoperative seizure activity.

surgery,clinical neurology
Pre-operative predictors of post-operative seizure control in low-grade glioma: a systematic review and meta-analysis

Khizar R Nandoliya,Vineeth Thirunavu,Erin Ellis,Karan Dixit,Matthew C Tate,Michael R Drumm,Jessica W Templer,Khizar R. Nandoliya,Matthew C. Tate,Michael R. Drumm,Jessica W. Templer

DOI: https://doi.org/10.1007/s10143-024-02329-9

IF: 2.8

2024-02-28

Neurosurgical Review

Abstract:As many as 80% of low-grade gliomas (LGGs) present with seizures, negatively impacting quality of life. While seizures are associated with gliomas regardless of grade, the importance of minimizing impact of seizures for patients with low grade tumors cannot be understated given the prolonged survival period in this population. The objective of this systematic review and meta-analysis was to summarize existing literature and identify factors associated with post-operative seizure control (defined as Engel I classification) in patients with LGGs, with a focus on pre-operative factors. Patient data extracted include tumor location and histology, pre-operative anti-seizure medication use, extent of resection (EOR), adjuvant treatment, pre-operative seizure type, duration, and frequency, and post-operative Engel classification. A random-effects model was used to calculate the effects of EOR, pre-operative seizure duration, adjuvant radiation, and adjuvant chemotherapy on post-operative seizure control. The effect of tumor location and histology on post-operative Engel I classification was determined using contingency analyses. Thirteen studies including 1628 patients with seizures were included in the systematic review. On meta-analyses, Engel I classification was associated with pre-operative seizure type (OR = 0.79 (0.63–0.99), p = 0.0385, focal versus generalized), frontal lobe LGGs (OR = 1.5 (1.1–2.0), p = 0.0195), and EOR (OR (95% CI) = 4.5 (2.3–6.7), p < 0.0001 gross-total versus subtotal). Pre-operative seizure duration less than one year, adjuvant radiation, adjuvant chemotherapy, and tumor histology were not associated with achieving Engel I classification. In addition to the known effects of EOR, Engel I classification is less likely to be achieved in patients with focal pre-operative seizures and more likely to be achieved in patients with frontal lobe LGGs.

surgery,clinical neurology
How Do E-Patients Connect Online? A Study of Social Support Roles in Health Social Networking

K. Chuang,Christopher C. Yang

DOI: https://doi.org/10.1007/978-3-642-37210-0_21

2013-04-02

Abstract:
1238 Next Generation Sequencing of Gliomas to Identify Predictors of Time to Postoperative Epilepsy

Minh P. Nguyen,Poojan Shukla,Jacob Young,Anthony T. Lee,Edward Chang

DOI: https://doi.org/10.1227/neu.0000000000002809_1238

IF: 5.315

2024-04-01

Neurosurgery

Abstract:INTRODUCTION: Seizures during the course of disease for patients with diffuse gliomas is common. As genetic characterization of gliomas has improved, how a tumors mutational profile influences the timing of postoperative seizures, and if postoperative seizures relate to survival and tumor progression, is poorly understood. METHODS: A retrospective review of consecutive adults from 2017 to 2020 who underwent resection of gliomas with next generation sequencing of tumors at a single institution was performed. Cox proportional hazards regression was performed to identify factors associated with time to postoperative seizures. Seizures within 72 hours of surgery were excluded. RESULTS: 363 patients with newly diagnosed or recurrent tumor tissue genotyped via next generation sequencing were included. Median follow-up time was 37.4 months, median time to seizure after surgery was 39.2 months (95% CI 34.6 – 60.8), and IDH-mutant tumors comprised 38.3% of the cohort. Patients with IDH-mutant tumors were more likely to have non-immediate postoperative seizures (p = 0.031) and more persistent postoperative seizures (p = 0.004) compared to IDH-wildtype tumors. PDGFRA mutation was associated with shorter time to seizure in IDH-mutant gliomas (p = 0.033), with no such genetic factors in IDH-wildtype tumors. Among IDH-mutant and wildtype tumors, patients with shorter seizure freedom had significantly shorter overall and progression-free survival. CONCLUSIONS: PDGFRA mutation is associated with earlier seizures after resection of IDH-mutant diffuse gliomas. Earlier first non-immediate postoperative seizure after resection is associated with worse overall and progression-free survival.

surgery,clinical neurology
The Analysis of Risk Factors and Survival Outcome for Chinese Patients with Epilepsy with High-Grade Glioma.

Zhengda Yu,Nan Zhang,N. U. Farrukh Hameed,Tianming Qiu,Dongxiao Zhuang,Junfeng Lu,Jinsong Wu

DOI: https://doi.org/10.1016/j.wneu.2019.01.213

IF: 2.21

2019-01-01

World Neurosurgery

Abstract:OBJECTIVE: To evaluate the risk factors of tumor-related epilepsy (TRE) and the relationship between TRE and functional/survival outcomes in patients with high-grade glioma (HGG). METHODS: The clinical data of 587 patients with HGG were retrospectively analyzed. A chi(2) test and logistic multiple-regression analysis were used to analyze factors associated with TRE. Logistic and Cox regression were used to analyze factors that may influence functional and survival outcomes. RESULTS: Glioma location in temporal (odds ratio [OR], 0.439; P = 0.04) and parietal lobes (OR, 0.092; P = 0.02) were independent protective factors of preoperative epilepsy, compared with gliomas of frontal lobe. Preoperative epilepsy (OR, 9.290; P < 0.001) and dominant hemispheric location (OR, 2.616; P = 0.04) were independent risk factors of postoperative epilepsy. On univariate analysis, patients with preoperative epilepsy had longer progression-free survival (PFS) (P = 0.001) and overall survival (OS) (P < 0.001). Multivariate analysis further confirmed that preoperative epilepsy was an independent protective factor of OS (hazard ratio, 0.587; P = 0.008). CONCLUSIONS: In patients with HGG, preoperative epilepsy is significantly associated with tumor involvement of the frontal lobe, whereas postoperative epilepsy is associated with preoperative epilepsy and dominant hemispheric location. Also, patients with HGG with preoperative epilepsy have better PFS and OS.
New-Onset Postoperative Seizures in Patients With Diffuse Gliomas: A Risk Assessment Analysis

Lianwang Li,Guanzhang Li,Shengyu Fang,Kenan Zhang,Ruoyu Huang,Yinyan Wang,Chuanbao Zhang,Yiming Li,Wei Zhang,Zhong Zhang,Qiang Jin,Dabiao Zhou,Xing Fan,Tao Jiang

DOI: https://doi.org/10.3389/fneur.2021.682535

IF: 3.4

2021-06-18

Frontiers in Neurology

Abstract:Background: Glioma-related epilepsy (GRE) is the most common presenting sign of patients with diffuse glioma. According to clinical experience, new-onset postoperative seizures can be observed even in patients without preoperative GRE. The current study mainly aimed to explore the risk factors of new-onset postoperative seizures in those patients. In addition, the prognostic value of new-onset postoperative seizures was also discussed. Methods: Data of 313 patients without GRE were retrospectively reviewed. Chi-square test or Fisher's exact test were first performed to compare categorical variables between patients with new-onset postoperative seizures and those without. Subsequently, binary logistic regression analysis was conduct to further assess risk factors of new-onset postoperative seizures. Kaplan-Meier and Cox analysis were used to investigate the prognostic value of new-onset postoperative seizures for progression-free survival (PFS) and overall survival (OS). Results: Patients with low-grade tumors ( p = 0.006), isocitrate dehydrogenase 1 (IDH1) mutation ( p = 0.040) or low Ki-67 expression ( p = 0.005) showed a higher incidence of new-onset postoperative seizures. IDH1 mutation was identified as the only independent predictor for new-onset postoperative seizures (OR, 2.075; 95% CI, 1.051–4.098; p = 0.035). Additionally, new-onset postoperative seizure occurrence was demonstrated as an independent predicter of prolonged OS (OR, 0.574; 95% CI, 0.335–0.983; p = 0.043), while younger age, gross total resection, low-grade and IDH1 mutation were independently correlated with prolonged OS and PFS. Conclusions: IDH1 mutation is an independent predictor for new-onset postoperative seizures in patients without preoperative GRE. Moreover, new-onset postoperative seizures can independently predict prolonged OS in those patients. The results of the current study can contribute to improving the individualized management of diffuse glioma.

neurosciences,clinical neurology
Motor seizures confer overall survival benefit in who grade 2 glioma

Sam Fairclough,Paul Chumas,John Goodden,Melissa Maguire,Ryan K. Mathew

DOI: https://doi.org/10.1111/epi.17956

IF: 6.74

2024-03-21

Epilepsia

Abstract:Objective The prevalence of epilepsy in World Health Organization (WHO) grade 2 glioma is high, with seizures being the presenting symptom in 60%–90%. We explore the epidemiology of seizures in this patient population in a regional neurosurgical center. Methods Electronic health records of patients with histologically‐proven WHO grade 2 glioma (n = 228) were reviewed between 1997 and 2021, with data collected including patient demographics, epilepsy prevalence, and seizure semiology. The influence of seizure type on overall survival was calculated using a Cox proportional hazards model. Results Overall, 197 of 228 patients (86.4%) were diagnosed with epilepsy—either at presentation or during the course of their disease. Male patients were more likely than female patients to be diagnosed with epilepsy (91.1% vs 77.1%, p = .003) and, in those with epilepsy, more likely to experience at least one focal to bilateral tonic–clonic seizure (69.4% vs 54.1%, p = .05). Patients with left‐sided tumors were twice as likely to have experienced a focal to bilateral tonic–clonic seizure (p = .02, odds ratio [OR] = .47). Predominantly experiencing seizures with motor activity appeared to confer better overall survival, with a 65% decrease in the risk of death 10 years post diagnosis (hazard ratio [HR] = .35, p = .02). This is despite accounting for previously described prognostic markers including tumor histology/genetics, time from diagnosis to surgery, and the extent of tumor resection. Significance Motor seizure activity is a frequent feature in WHO grade 2 glioma and appears to confer a survival benefit regardless of histology or surgical factors. Seizures due to dominant hemisphere tumors may be more likely to propagate and cause bilateral tonic–clonic activity.

clinical neurology
Extra-temporal pediatric low-grade gliomas and epilepsy

José Hinojosa,Victoria Becerra,Santiago Candela-Cantó,Mariana Alamar,Diego Culebras,Carlos Valencia,Carlos Valera,Jordi Rumiá,Jordi Muchart,Javier Aparicio

DOI: https://doi.org/10.1007/s00381-024-06573-8

2024-08-27

Abstract:Low-grade gliomas, especially glioneuronal tumors, are a common cause of epilepsy in children. Seizures associated with low-grade pediatric tumors are medically refractory and present a significant burden to patients. Often, morbidity and patients´ quality of life are determined rather by the control of seizures than the oncological process itself and the resolution of epilepsy represents an important part in the treatment of LGGs. The pathogenesis of tumor-related seizures in focal LGG tumors is multifactorial, and mechanisms differ probably among patients and tumor types. Pediatric low-grade tumors associated with epilepsy include a series of neoplasms that have a pure astrocytic or glioneuronal lineage. They are usually benign tumors with a neocortical localization typically in the temporal lobes, but also in other supratentorial locations. Gangliogliomas and dysembryoplastic neuroepithelial tumors (DNET) are the most common entities together with astrocytic gliomas (pilocytic astrocytomas and pleomorphic xanthoastrocytoma) and angiocentric gliomas, and dual pathology is found in up to 40% of glioneuronal tumors. The treatment of low-grade gliomas and associated epilepsy is based mainly on resection and the extent of surgery is the main predictor of postoperative seizure control in patients with a LGG. Long-term epilepsy-associated tumors (LEATs) tend to be well-circumscribed, and therefore, the chances for a complete resection and epilepsy control with a safe approach are very high. New treatments have emerged as alternatives to open microsurgical approaches, including laser thermal ablation or the use of BRAF inhibitors. Future advances in identifying seizure-related biomarkers and molecular tumor pathways will facilitate targeted treatment strategies that will have a deep impact both in oncologic and epilepsy outcomes.
Antiepileptic Strategies for Patients with Primary and Metastatic Brain Tumors

Herbert B. Newton,Jenna Wojkowski

DOI: https://doi.org/10.1007/s11864-024-01182-8

2024-02-15

Current Treatment Options in Oncology

Abstract:Seizure activity is common in patients with primary and metastatic brain tumors, affecting more than 50% of cases over the course of their disease. Several mechanisms contribute to brain tumor–related epilepsy (BTRE), including a pro-inflammatory environment, excessive secretion of glutamate and an increase in neuronal excitatory tone, reduction of GABAergic inhibitory activity, and an increase in 2-hydroxygluturate production in isocitrate dehydrogenase mutant tumors. After a verified seizure in a brain tumor patient, the consensus is that BTRE has developed, and it is necessary to initiate an antiepileptic drug (AED). It is not recommended to initiate AED prophylaxis. Second- and third-generation AEDs are the preferred options for initiation, due to a lack of hepatic enzyme induction and reduced likelihood for drug-drug interactions, especially in regard to neoplastic treatment. The efficacy of appropriate AEDs for patients with BTRE is fairly equivalent, although some data suggests that levetiracetam may be slightly more active in suppressing seizures than other AEDs. The consensus among most Neuro-Oncology providers is to initiate levetiracetam monotherapy after a first seizure in a brain tumor patient, as long as the patient does not have any psychiatric co-morbidities. If levetiracetam is not tolerated well or is ineffective, other appropriate initial AED options for monotherapy or as an add-on anticonvulsant include lacosamide, valproic acid, briviracetam, lamotrigine, and perampanel.

oncology

[Obtainment of cerebral evoked potentials at the time of stimulation of micromelic extremities].

Brain tumor related epilepsy: pathophysiological approaches and rational management of antiseizure medication

Wild Seizing Gliomas! Time-Dependent Characteristics and Prognosis of Glioblastoma-Related Epilepsy

Glioma-related epilepsy in patients with diffuse high-grade glioma after the 2016 WHO update: seizure characteristics, risk factors, and clinical outcomes

Seizures in glioma patients: An overview of incidence, etiology, and therapies

The Potential of Seizure to Predict Prognosis in Glioblastoma Patients: A retrospective Study

Postoperative seizure control in patients with tumor-associated epilepsy

The Clinical Features and Influencing Factors of Surgical Efficacy in Glioneuronal Tumors Associated-Epilepsy

Clinical Characteristics of Low‐grade Tumor‐related Epilepsy and Its Predictors for Surgical Outcome

Long-term seizure outcome after epilepsy surgery of neuroglial tumors

Glioma-related epilepsy following low-grade glioma surgery

To be or not to be: The dilemma over the prognostic role of epilepsy at presentation in patients with glioblastoma – a systematic review and meta-analysis

Next Generation Sequencing Mutational Profiles of Gliomas Reveal Clinical and Genetic Factors Predicting Refractory Postoperative Seizures

Pre-operative predictors of post-operative seizure control in low-grade glioma: a systematic review and meta-analysis

How Do E-Patients Connect Online? A Study of Social Support Roles in Health Social Networking

1238 Next Generation Sequencing of Gliomas to Identify Predictors of Time to Postoperative Epilepsy

The Analysis of Risk Factors and Survival Outcome for Chinese Patients with Epilepsy with High-Grade Glioma.

New-Onset Postoperative Seizures in Patients With Diffuse Gliomas: A Risk Assessment Analysis

Motor seizures confer overall survival benefit in who grade 2 glioma

Extra-temporal pediatric low-grade gliomas and epilepsy

Antiepileptic Strategies for Patients with Primary and Metastatic Brain Tumors